press releases

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in… Read More

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the INNOVATE trial,… Read More

Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine Metastatic pancreatic cancer patients treated with TTFields therapy combined with gemcitabine had a median overall survival of 8.3 months May 18, 2016 05:00 PM… Read More

Results demonstrate that TTFields enhance immunogenic cell death in non-small cell lung cancer cells in vivo Data suggest combining TTFields with anti-PD-1 may achieve tumor control by further enhancing antitumor immunity May 13, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS… Read More

May 11, 2016 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today announced that it has entered into an employment agreement with William Doyle, current Chairman and Director, to formally establish his role… Read More

Increasing adoption of Optune with 755 prescriptions received in the first quarter 2016, an increase of 73 percent from the first quarter 2015 and 36 percent from the fourth quarter 2015 797 active patients at March 31, 2016, an increase of 114 percent from March 31, 2015… Read More

New programs respond to unmet needs described by the GBM community May 06, 2016 07:35 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today it will deliver new programs to support the glioblastoma (GBM) community during Brain Tumor Awareness Month. Last year,… Read More

Website and traveling exhibit to support glioblastoma community May 05, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today the availability of a new online resource to raise awareness of glioblastoma (GBM) and share stories of inspiration with the GBM… Read More

More than 112 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma May 04, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Blue Cross Blue Shield of Michigan now covers Optune… Read More